指南与共识类风湿关节炎

EULAR 2025年类风湿关节炎合成及生物改善病情抗风湿药管理建议更新

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.
指南 / 共识 · Ann Rheum Dis · 2026-03-13

欧洲风湿病联盟(EULAR)国际工作组基于两项系统文献研究更新了2025年类风湿关节炎管理建议,最终形成5项总体原则和9条推荐。推荐起始甲氨蝶呤(MTX)理想联合短期糖皮质激素,3至6个月应答不足加用生物DMARD;充分考虑主要心血管事件、恶性肿瘤和血栓栓塞风险后可考虑JAK抑制剂;持续缓解可减量但停药常致复发。

要点

  • 起始治疗推荐MTX,理想联合短期糖皮质激素。
  • 3至6个月应答不足应加用bDMARD;评估风险后可考虑JAKi。
  • 首个bDMARD或JAKi失败后可换用其他bDMARD或JAKi。

核心结论

  • 更新版EULAR推荐基于疗效、安全性和成本证据,为RA管理提供共识。

研究设计与样本

  • 国际工作组开展两项系统文献研究,评估DMARDs的安全性和有效性,经投票形成推荐并评定证据等级和推荐强度。

主要发现

  • 工作组就5项总体原则和9条推荐达成一致,涉及csDMARDs、糖皮质激素、bDMARDs和tsDMARDs的使用。
  • 推荐涵盖单药治疗、联合治疗、达标治疗策略及临床缓解后减量。
  • 安全性方面考虑主要心血管事件(MACEs)、恶性肿瘤、成本及b/tsDMARDs的顺序。

关键数值与推荐

  • 起始推荐MTX,理想联合短期糖皮质激素。
  • MTX应答不足3至6个月后应加用bDMARD。
  • 充分考虑MACEs、恶性肿瘤和/或血栓栓塞事件风险后,可考虑JAKi。
  • 首个bDMARD或JAKi失败后,推荐换用其他bDMARD(同类或不同类)或JAKi(需考虑风险)。
  • 持续缓解可减量DMARD,但需谨慎,因停药常导致复发。

临床怎么用

  • RA患者起始MTX联合短期糖皮质激素,3至6个月应答不足加用bDMARD。
  • 使用JAKi前需评估MACEs、恶性肿瘤和血栓栓塞风险。
  • 首个bDMARD或JAKi失败后可换用其他bDMARD或JAKi。
  • 持续缓解者可谨慎减量DMARD,避免直接停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to provide an update of the European Alliance of Associations for Rheumatology (EULAR) rheumatoid arthritis (RA) management recommendations addressing the most recent insights. METHODS: An International Task Force was formed with a wide expertise and solicited 2 systemic literature research activities on the safety and efficacy of disease-modifying antirheumatic drugs (DMARDs). New evidence was discussed, considering the update from 2022. A voting process was applied to each item. Levels of evidence and strengths of recommendation were assigned, and participants voted on the levels of agreement. RESULTS: The task force agreed on 5 overarching principles and reduced the number of recommendations to 9 concerning use of conventional synthetic DMARDs (methotrexate [MTX], leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b)DMARDs (tumour necrosis factor inhibitors [adalimumab, certolizumab pegol, etanercept, golimumab, infliximab], abatacept, rituximab, tocilizumab, sarilumab, including biosimilars) and targeted synthetic [ts]DMARDs (namely the Janus kinase inhibitors [JAKi] tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target), and tapering following clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were considered. Initially, MTX ideally in combination with short-term GCs is recommended; upon insufficient response after 3 to 6 months, a bDMARD should be added; after careful consideration of risks, including MACEs, malignancies and/or thrombo-embolic events, JAKi may also be considered. If the first bDMARD (or JAKi) fails, any other bDMARD (from another or the same class) or JAKi (considering risks) is recommended. With sustained remission, DMARDs may be tapered, but caution is required as stopping often leads to a flare. Levels of evidence and levels of agreement were high for most recommendations. CONCLUSIONS: These updated EULAR recommendations provide consensus on RA management based on currently available evidence regarding efficacy, safety, and cost.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026. PMID: 41826212. doi:10.1016/j.ard.2026.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。